301 related articles for article (PubMed ID: 20068398)
1. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.
Peipp M; Dechant M; Valerius T
MAbs; 2009; 1(6):590-9. PubMed ID: 20068398
[TBL] [Abstract][Full Text] [Related]
2. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
3. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
Caraglia M; Marra M; Meo G; Addeo SR; Tagliaferri P; Budillon A
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):209-22. PubMed ID: 18221038
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor as a target for anti-cancer agent design.
Cao J; Fang H; Wang B; Ma C; Xu W
Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
[TBL] [Abstract][Full Text] [Related]
5. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?
Sabbatino F; Ferrone S
Clin Cancer Res; 2013 Mar; 19(5):958-60. PubMed ID: 23340298
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
7. Role of an anti-epidermal growth factor receptor in treating cancer.
Waksal HW
Cancer Metastasis Rev; 1999; 18(4):427-36. PubMed ID: 10855786
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies targeting the epidermal growth factor receptor.
Bianco R; Daniele G; Ciardiello F; Tortora G
Curr Drug Targets; 2005 May; 6(3):275-87. PubMed ID: 15857288
[TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
10. ErbB-targeted therapeutic approaches in human cancer.
Arteaga CL
Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
[TBL] [Abstract][Full Text] [Related]
11. Targeting the ERBB family in cancer: couples therapy.
Tebbutt N; Pedersen MW; Johns TG
Nat Rev Cancer; 2013 Sep; 13(9):663-73. PubMed ID: 23949426
[TBL] [Abstract][Full Text] [Related]
12. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.
Dempke WCM; Heinemann V
Eur J Cancer; 2009 May; 45(7):1117-1128. PubMed ID: 19124237
[TBL] [Abstract][Full Text] [Related]
13. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
Sun GC; Yang X; Yu Y; Zhao DW
Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to HER family targeting antibodies.
Kruser TJ; Wheeler DL
Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
Moreira J; Tobias A; O'Brien MP; Agulnik M
Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
[TBL] [Abstract][Full Text] [Related]
18. The ErbB receptors as targets for breast cancer therapy.
Albanell J; Baselga J
J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):337-51. PubMed ID: 10705918
[TBL] [Abstract][Full Text] [Related]
19. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
Markovic A; Chung CH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
